Alabama is currently home to 1294 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Feasibility of An Active Video Gaming Intervention
NCT05310279
Recruiting
Replacing sedentary behaviors during leisure time with active video gaming (AVG) has been shown to be an enjoyable option for increasing the amount of physical activity acquired each week. This project will examine the feasibility of an AVG intervention using the GAIMplank.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: WHARF, Homewood, Alabama
Conditions: Physical Disability
Register for Updates
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747
Recruiting
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/24/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Register for Updates
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
NCT05146739
Recruiting
This phase I trial tests the safety, side effects, and best dose of uproleselan in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that has come back (relapsed) or does not respond to treatment (refractory) and that expresses E-selectin ligand on the cell membrane. Uproleselan binds to E-selectin expressed on endothelial cells of the bone marrow and prevents their interaction with selectin-E... Read More
Gender:
All
Ages:
17 years and below
Trial Updated:
04/24/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy
Register for Updates
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04987307
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2024
Locations: Digestive Health Specialists of the Southeast, Dothan, Alabama
Conditions: Ulcerative Colitis
Register for Updates
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
NCT04973605
Recruiting
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409
Recruiting
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/24/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Low Grade Glioma, Low Grade Astrocytoma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
Register for Updates
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619
Recruiting
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/24/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Register for Updates
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
NCT03684980
Recruiting
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Central Nervous System Lymphoma
Register for Updates
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06182072
Recruiting
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama
Conditions: Pancreatic Ductal Carcinoma
Register for Updates
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177
Recruiting
The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: Amount and quality of pain Interference with p... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2024
Locations: East Alabama Arthritis Center, Auburn, Alabama
Conditions: Sciatica Acute, Lumbar Spinal Stenosis
Register for Updates
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF
NCT06144632
Recruiting
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: Grandview Medical Center, Birmingham, Alabama
Conditions: Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Accel Research Sites Network, Birmingham, Alabama
Conditions: Obesity
Register for Updates